SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-23-003162
Filing Date
2023-03-06
Accepted
2023-03-06 07:07:24
Documents
13
Period of Report
2023-03-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K stok-8k_20230306.htm   iXBRL 8-K 37037
2 EX-99.1 stok-ex991_7.htm EX-99.1 323085
  Complete submission text file 0001564590-23-003162.txt   507954

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA stok-20230306.xsd EX-101.SCH 5625
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE stok-20230306_lab.xml EX-101.LAB 19308
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stok-20230306_pre.xml EX-101.PRE 11510
7 EXTRACTED XBRL INSTANCE DOCUMENT stok-8k_20230306_htm.xml XML 3541
Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

IRS No.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38938 | Film No.: 23707531
SIC: 2834 Pharmaceutical Preparations